Anti-fibrotic Drug Discovery

Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.

From the book series:
Drug Discovery

Anti-fibrotic Drug Discovery Editors: Jehrod Brenneman, Malliga R Iyer

Front Matter

Preface

Contents

TGFβ Signaling

Targeting the αv Integrins in Fibroproliferative Disease

Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators

Autotaxin Inhibitors in Fibrosis

Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology

Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis

Galectin-3 Involvement in Fibrotic Diseases

Emerging Role of CXCR4 in Fibrosis

BH3 Mimetic Drugs for Anti-fibrotic Therapy

Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities

Targeting Fibroblasts in Fibrosis and Cancer

Subject Index

Publication details

About this book